EP0831793A4 - Protein particles for therapeutic and diagnostic use - Google Patents

Protein particles for therapeutic and diagnostic use

Info

Publication number
EP0831793A4
EP0831793A4 EP96918313A EP96918313A EP0831793A4 EP 0831793 A4 EP0831793 A4 EP 0831793A4 EP 96918313 A EP96918313 A EP 96918313A EP 96918313 A EP96918313 A EP 96918313A EP 0831793 A4 EP0831793 A4 EP 0831793A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic
diagnostic use
protein particles
protein
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96918313A
Other languages
German (de)
French (fr)
Other versions
EP0831793A1 (en
Inventor
Richard C K Yen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemosphere Inc
Original Assignee
Hemosphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/471,650 external-priority patent/US5725804A/en
Application filed by Hemosphere Inc filed Critical Hemosphere Inc
Publication of EP0831793A1 publication Critical patent/EP0831793A1/en
Publication of EP0831793A4 publication Critical patent/EP0831793A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
EP96918313A 1995-06-06 1996-06-04 Protein particles for therapeutic and diagnostic use Withdrawn EP0831793A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/471,650 US5725804A (en) 1991-01-15 1995-06-06 Non-crosslinked protein particles for therapeutic and diagnostic use
US471650 1995-06-06
US55491995A 1995-11-09 1995-11-09
US554919 1995-11-09
PCT/US1996/009458 WO1996039128A1 (en) 1995-06-06 1996-06-04 Protein particles for therapeutic and diagnostic use

Publications (2)

Publication Number Publication Date
EP0831793A1 EP0831793A1 (en) 1998-04-01
EP0831793A4 true EP0831793A4 (en) 2000-11-15

Family

ID=27043520

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96918313A Withdrawn EP0831793A4 (en) 1995-06-06 1996-06-04 Protein particles for therapeutic and diagnostic use

Country Status (5)

Country Link
EP (1) EP0831793A4 (en)
JP (1) JPH11507630A (en)
AU (1) AU6100296A (en)
CA (1) CA2220895A1 (en)
WO (1) WO1996039128A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69731985T2 (en) * 1996-10-21 2005-12-29 Quadrant Drug Delivery Ltd., Ruddington BLANK SPARE PARTS AND SUITABLE CONJUGATION MANUFACTURING PROCESS
EP0860167A1 (en) * 1997-01-30 1998-08-26 Robert Gurny RNA-and DNA- based active agents in nanoparticles
CA2294494A1 (en) * 1997-06-05 1998-12-10 Richard C. K. Yen Fibrinogen-coated microspheres
GB9724143D0 (en) 1997-11-14 1998-01-14 Andaris Ltd Pharmaceutical conjugate
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
DK2280020T3 (en) * 1999-06-29 2016-05-02 Mannkind Corp Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US20090280534A1 (en) * 2004-12-22 2009-11-12 Novozymes A/S Recombinant Production of Serum Albumin
CA2618439A1 (en) * 2005-08-12 2007-02-22 Astellas Pharma Inc. Technique for stabilization of yw753 reparation
DE102006011507A1 (en) 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Active substance-loaded nanoparticles based on hydrophilic proteins
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
US9351925B2 (en) * 2011-09-10 2016-05-31 Richard C. K. Yen Submicron particles to decrease transfusion
US10603287B2 (en) * 2016-07-20 2020-03-31 Ptlnv, Llc, Series Three (3) Albumin nanosphere preparations to control bleeding from surgical operations
KR101167285B1 (en) * 2011-11-18 2012-07-23 에이앤펩주식회사 Niacin-peptides having skin whitening effect and uses thereof
CN110139662B (en) 2017-07-05 2022-03-18 江阴贝瑞森制药有限公司 Anti-inflammatory use of peptides
WO2019228307A1 (en) * 2018-05-28 2019-12-05 Jiangyin Usun Pharmaceutical Co., Ltd. New pharmaceutical use
CN113797861B (en) * 2021-09-16 2024-03-29 江苏月旭新材料科技有限公司 Hydroxypropyl glucan microsphere and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4147767A (en) * 1975-10-09 1979-04-03 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565559A (en) * 1968-03-11 1971-02-23 Sumitomo Chemical Co Process for making microcapsules
US4325937A (en) * 1977-09-22 1982-04-20 Battelle Development Corporation Microbial insecticide
CH652599A5 (en) * 1981-08-28 1985-11-29 Solco Basel Ag Method for producing colloidal physiological degradable, human serum albumin containing products and their use.
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5104674A (en) * 1983-12-30 1992-04-14 Kraft General Foods, Inc. Microfragmented ionic polysaccharide/protein complex dispersions
SE459005B (en) * 1985-07-12 1989-05-29 Aake Rikard Lindahl SET TO MANUFACTURE SPHERICAL POLYMER PARTICLES
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
JPS6418439A (en) * 1987-07-14 1989-01-23 Nippon Oils & Fats Co Ltd Powdery fat coated with crosslinked coating and its manufacture
JPH0813750B2 (en) * 1990-03-01 1996-02-14 持田製薬株式会社 Oral thrombin formulation
US5374441A (en) * 1992-02-04 1994-12-20 Rutgers, The State University Of New Jersey Heat stable fat substitute compositions and process

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4147767A (en) * 1975-10-09 1979-04-03 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9639128A1 *

Also Published As

Publication number Publication date
CA2220895A1 (en) 1996-12-12
AU6100296A (en) 1996-12-24
WO1996039128A1 (en) 1996-12-12
EP0831793A1 (en) 1998-04-01
JPH11507630A (en) 1999-07-06

Similar Documents

Publication Publication Date Title
HUP9801390A3 (en) Radiolabeled peptides for diagnosis and therapy
AU7383298A (en) Novel antiangiogenic peptide agents and their therapeutic and diagnostic use
IL122216A0 (en) Dolastatin derivatives their preparation and use
IL110464A0 (en) Novel proteins for the diagnosis, imaging, and therapy of human cancer
EP0831793A4 (en) Protein particles for therapeutic and diagnostic use
HK1043937A1 (en) Human therapeutic uses of bpi protein products
IL106037A0 (en) Therapeutic and diagnostic methods based on neurotrophin-4-expression
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
GB9419021D0 (en) Therapeutic protein
AU4441093A (en) Ultrasonic apparatus for health and beauty
GB9514816D0 (en) Substances and their medical use
IL116658A0 (en) Peptides their preparation and use
GB9517697D0 (en) Ultrasound bone analysers and methods for sensing body part
EP0841393A4 (en) HUMAN GALECTIN-4-LIKE PROTEIN AND cDNA ENCODING THE SAME
ZA976547B (en) Lipid-binding proteins and their therapeutic and diagnostic use
IL112681A0 (en) Opioid peptides for the treatment of pain and use thereof
HK1024006A1 (en) Peptide as diagnostic and therapeutic agent for autoimmune diseases
GB9523066D0 (en) Compounds and their therapeutic use
EP0857732A4 (en) Human pec-60-like protein and dna encoding the same
AU4499196A (en) Antibodies for use in cancer therapy and diagnosis
AU5279996A (en) Antibodies and their use in cancer therapy and diagnosis
AUPN691195A0 (en) Therapeutic and diagnostic compositions - B
AUPN691095A0 (en) Therapeutic and diagnostic compositions - A
AUPN685995A0 (en) Therapeutic and diagnostic compositions - II
AUPN685895A0 (en) Therapeutic and diagnostic compositions - I

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 971224;LT PAYMENT 971224;LV PAYMENT 971224;SI PAYMENT 971224

A4 Supplementary search report drawn up and despatched

Effective date: 20000928

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 9/64 A, 7A 61K 31/74 B, 7A 61K 38/38 B, 7B 01J 13/02 B, 7A 61K 9/16 B, 7A 61K 38/36 B, 7A 61K 9/51 B

17Q First examination report despatched

Effective date: 20020423

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020903